A comparative evaluation of safety and efficacy of Rosuvastatin, Simvastatin, and Atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia

Mohammed Mudassir  Ali; Syed Mustafa Ashraf; Umrana Mirza; Juwairia Mohammed Fariduddin

doi:10.53730/ijhs.v6nS1.6577

Authors

Mohammed Mudassir Ali Assistant Professor, Department of General Medicine, Deccan College of Medical Sciences, Hyderabad, Telangana, India
Syed Mustafa Ashraf Professor, Department of General Medicine, Prathima Institute of Medical Sciences, Karimnagar, Telangana, India
Umrana Mirza Assistant professor, Department of Biochemistry, ShadanInstitute ofMedical Sciences, Hyderabad,Telangana,India
Juwairia Mohammed Fariduddin Consultant Biochemist, Fernandez Hospital Hyderguda, Hyderabad, Telangana, India. Corresponding Author: Dr Juwairia Mohammed Fariduddin

Keywords:

Atorvastatin, dyslipidemia, Rosuvastatin, simvastatin, type-2 diabetes mellitus

Abstract

Introduction: Type 2 diabetes mellitus consists of an array of dysfunctions characterized by hyperglycaemia and resulting from the combination of resistance to insulin action, inadequate insulin secretion, and excessive or inappropriate glucagon secretion. Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. The characteristic features of diabetic dyslipidemia are a high plasma triglyceride concentration, low HDL cholesterol concentration and increased concentration of small dense LDL-cholesterol particles. To evaluate and compare the safety and efficacy of Rosuvastatin, simvastatin, and atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia. Material and Method: This is prospective, comparative, open label, randomized and parallel group. The subjects enrolled for this study were selected from the Out-Patient Department of Medicine collaboration with Department of Biochemistry and Pharmacology, Tertiary care teaching hospital over a period of month. Newly diagnosed 120 cases of patients of Type II Diabetes Mellitus well controlled on oral hypoglycemic drugs were randomly divided into 3 groups of 40 each. Group A: Simvastatin 10 mg O.D and Group B was received Atorvastatin 10 mg O.D and Group C was received Rosuvastatin 10 mg O.D for 3 months.

Downloads

Download data is not yet available.

References

Mandal N, Grambergs R, Mondal K, Basu SK, Tahia F, Dagogo-Jack S. Role of ceramides in the pathogenesis of diabetes mellitus and its complications. J Diabetes Complications. 2021;35(2):107734.

Pradeepa, Rajendra; Mohan, Viswanathan, Epidemiology of type 2 diabetes in India, Indian Journal of Ophthalmology: November 2021 - Volume 69 - Issue 11 - p 2932-2938

Alrasheed AA. Dyslipidemia Among Patients With Type 1 Diabetes and Its Associated Factors in Saudi Arabia: An Analytical Cross-Sectional Study. Cureus. 2022;14(2):e21923.

Hess CN, Low Wang CC, Hiatt WR. PCSK9 inhibitors: mechanisms of action, metabolic effects, and clinical outcomes. Annu Rev Med. 2018; 69:133–145.

Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL Global epidemiology of dyslipidaemias.. Nat Rev Cardiol. 2021;18:689–700.

Al-Zahrani J, Shubair MM, Al-Ghamdi S, et al. The prevalence of hypercholesterolemia and associated risk factors in Al-Kharj population, Saudi Arabia: a cross-sectional survey. BMC Cardiovasc Disord. 2021;21:22.

Soliman H, Ibrahim A. Prevalence and pattern of dyslipidemia in an Egyptian children and adolescents with type 1 diabetes. Egypt Pediatr Assoc Gaz. 2021;69:1–7.

Cosentino F, Grant PJ, Aboyans V, et al; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323.

Vergès B. Dyslipidemia in type 1 diabetes: a masked danger. Trends Endocrinol Metab. 2020;31:422–434.

Nelson AJ, O’Brien EC, Kaltenbach LA, et al. Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. JAMA Netw Open. 2022;5(2):e2148030.

Cannon CP, Pratley R, Dagogo-Jack S, et al; VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425-1435.

Arnold SV, de Lemos JA, Rosenson RS, et al; GOULD Investigators. Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease. Circulation. 2019;140(7):618-620.

Nanna MG, Wang TY, Xiang Q, et al. Sex differences in the use of statins in community practice. Circ Cardiovasc Qual Outcomes. 2019;12(8):e005562.

Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-2229.

Cosentino F, Grant PJ, Aboyans V, et al; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323.

Das SR, Everett BM, Birtcher KK, et al. 2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(9):1117-1145.

Li S, Wang J, Zhang B, Li X, Liu Y. Diabetes mellitus and cause-specific mortality: a population-based study. Diabetes Metab J. 2019;43:319–341.

Abed E, LaBarbera B, Dvorak J, Zhang Y, Beck J, Talsania M. Prevalence of dyslipidemia and factors affecting dyslipidemia in young adults with type 1 diabetes: evaluation of statin prescribing. J Pediatr Endocrinol Metab. 2019;32:327–334.

Zabeen B, Balsa AM, Islam N, Parveen M, Nahar J, Azad K. Lipid profile in relation to glycemic control in type 1 diabetes children and adolescents in Bangladesh. Indian J Endocrinol Metab. 2018;22:89–92.

Robert AA, Al-Dawish A, Mujammami M, Dawish MA. Type 1 diabetes mellitus in Saudi Arabia: a soaring epidemic. Int J Pediatr. 2018;2018:9408370.

Zhang Z, Wu P, Zhang J, Wang S, Zhang G. The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis. Pharmacol Res. 2016 Mar; 105:74-83.

Unnikrishnan R, Anjana RM, Mohan V. Diabetes mellitus and its complications in India. Nat Rev Endocrinol. 2016; 12(6):357–370.

Rosada A, Kassner U, Weidemann F, König M, Buchmann N, Steinhagen-Thiessen E, Spira D.Hyperlipidemias in elderly patients: results from the Berlin Aging Study II (BASEII), a cross-sectional study. Lipids Health Dis. 2020;19:92.

Khan MA, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. J Epidemiology of type 2 diabetes-global burden of disease and forecasted trends. Epidemiol Glob Health. 2020;10:107–111.

Bancks MP, Ning H, Allen NB, et al. Long-term absolute risk for cardiovascular disease stratified by fasting glucose level. Diabetes Care. 2019;42(3):457-465.

López-Jaramillo P, Gómez-Arbeláez D, López-López J, et al.: The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Hormone Mol Biol Clin Invest. 2014, 18:37-45.

Barakat L, Jayyousi A, Bener A, Zuby B, Zirie M. Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemia Diabetic Patients. ISRN Pharmacol. 2013; 2013:146579.

Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.

Goudevenos JA ,Bairaktari ET,Chatzidimou DP,Elisaf MS .The effect of Atorvastatin on serum lipids ,Lipoprotein (a) & plasma fibrinogen levels in primary dyslipidaemia –A pilot Study involving serial Sampling. Curr. Med. Res. Opin. 2001 ; 16 : 269 -75.

Hunninghake DB ,Ballantyne CM ,Maccubin DL ,Shah AK , Gumbiner B , Mitchel YB, Conparative effects of Simvastatin and Atorvastatin in Hypercholesterolemic patients with characteristics of metabolic syndrome . clin ther 2003 ; 25 : 1679-86.